Panacea Bio is currently trading at Rs. 75.95, up by 0.70 points or 0.93% from its previous closing of Rs. 75.25 on the BSE.
The scrip opened at Rs. 74.05 and has touched a high and low of Rs. 77.50 and Rs. 74.05 respectively. So far 2786 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 199.45 on 26-Apr-2011 and a 52 week low of Rs. 70.00 on 30-Dec-2011.
Last one week high and low of the scrip stood at Rs. 79.00 and Rs. 74.05 respectively. The current market cap of the company is Rs. 465.20 crore.
The promoters holding in the company stood at 74.85% while Institutions and Non-Institutions held 3.18% and 21.97% respectively.
Drug firm, Panacea Biotec has withdrawn its oral polio vaccine from the World Health Organisation’s (WHO) list of pre-qualified vaccines stating the facility where the vaccine is being manufactured needs further corrective actions. The company withdrew the vaccine despite undertaking several measures regarding refurbishment of the facility and strengthening of QMS from September to December, 2011.
A team from WHO has audited the company’s manufacturing facility at Okhla in the capital from January 3 to February 1, to assess the quality management systems (QMS) applied to production and control of oral polio vaccines (OPV). WHO reported that OPV produced by the company will no longer be supplied through United Nations (UN) agencies.
The company, however, will continue to supply OPVs which were produced prior to the production halt in September 2011, as monitoring and testing of these lots confirm compliance with quality specifications.
Panacea Biotec is one of India’s leading research based health management companies with established research, manufacturing and marketing capabilities.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1670.20 |
| Dr. Reddys Lab | 1235.00 |
| Cipla | 1232.20 |
| Zydus Lifesciences | 936.50 |
| Lupin | 2331.65 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: